GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1) that currently has only one completed phase I clinical trial for non-Hodgkin’s lymphoma. The gene discussed is PLK1; the disease is non-Hodgkin lymphoma.